skip to main content
iatroX JournalClinical AI

Doximity Ask vs OpenEvidence After the UpToDate Deal

Featured image for Doximity Ask vs OpenEvidence After the UpToDate Deal

The old comparison between a workflow assistant and an evidence-search tool is no longer sufficient. Both Doximity Ask and OpenEvidence deserve to be assessed as clinical information products whose usefulness depends on the interaction between sources, access and the clinician's working environment.

DoxGPT remains a familiar search term, but Doximity's Clinical AI Suite announcement identifies Ask as its successor name. The UpToDate development strengthens the case for reassessing the comparison. It does not supply the results of a head-to-head trial.

Start with the clinical job

A busy outpatient physician may need to clarify a recommendation, prepare an explanation and complete an administrative task in one sitting. A specialist exploring a difficult literature question may prioritise detailed source inspection. Neither user is served well by a comparison that ranks products solely by the number of features advertised.

The first physician should examine transitions between tasks. The second should examine evidence coverage, the fidelity of synthesis and the effort required to inspect a paper's methods. Both should check whether the answer preserves the population, setting and degree of uncertainty in the source.

This task-first approach avoids a common error: declaring a product better because its strongest demonstration happens to match the reviewer's favourite use case. A useful recommendation names the task for which the advantage is expected and the observation that would confirm it.

Doximity's suite is a distribution advantage, not a clinical verdict

Doximity's desktop announcement places Ask alongside its other clinical tools on the workstation. The strategic advantage is proximity. A clinician who already uses that environment may face less friction when a reference question arises.

Proximity can encourage adoption even before a product establishes superior answers. That is not inherently problematic. A well-designed tool that is actually used can be valuable. The concern arises when convenience is mistaken for evidence of accuracy, or when a clinician stops considering another source because switching has become inconvenient.

The UpToDate addition should therefore be assessed for its incremental contribution. Does it reveal an exception, improve access to an authored account or make a disagreement easier to resolve? Merely repeating a similar answer would add less value than the branding suggests.

OpenEvidence is also pursuing institutional access

OpenEvidence's Northwestern collaboration, announced on 12 October, describes access from Epic using existing hospital credentials, with rollout beginning on 8 October. That is enough to reject the idea that OpenEvidence is only a detached browser destination.

It is not enough to assume comprehensive patient-record interpretation. Authentication, launch location and clinical context are distinct technical properties. A comparison should record what is actually transferred and what the clinician must still enter.

The practical implication is that institutional implementation can change the answer to "which should I open first?" A doctor whose employer has enabled a convenient, supported route may reasonably favour it for routine queries, while retaining another resource for deeper checking.

Compare evidence behaviour rather than publisher counts

A broad collection can still produce a narrow answer. A carefully maintained collection can still be applied to the wrong question. Source breadth and source selection should therefore be reviewed separately.

One useful test concerns disagreement. Give each product an original educational question in which two sources appear to recommend different approaches. Look for an explanation of population, date and decision context. A response that simply chooses one authority is less informative than a response that identifies why the recommendations are not directly comparable.

Another test concerns missing information. A question that omits a relevant measurement should prompt qualification rather than invented precision. These are proposed assessment tasks, not claims about observed performance by either product.

Human review needs a specific meaning

Doximity's public terms distinguish selected human-reviewed outputs from outputs that have not been individually reviewed. That distinction should remain visible in any discussion of PeerCheck. A programme involving clinicians is not the same as a named clinician reviewing every new response.

The same discipline applies to any competing claim about expert involvement. Ask who reviewed what, when the review occurred and whether subsequent generation can alter the reviewed material. A review label is informative only to the extent that its scope is understood.

For a clinician, the useful outcome is not reassurance in the abstract. It is an identifiable reason to trust a specific statement, together with an accessible route to investigate it.

Where iatroX offers a different decision

For a reader focused on UK applicability or examination learning, the best choice may not be a winner between two US-oriented platforms. iatroX's clinical guidance directory makes regional context explicit, while its question-bank workspace addresses practice rather than only retrieval.

That combination is especially relevant when the clinician's question is followed by another: "Why did I misunderstand this, and how do I avoid repeating it?" An evidence-search application can help explain the topic, but a structured learning activity supplies a different form of engagement.

iatroX should be evaluated on that concrete contribution. It does not need an unsupported universal accuracy claim to justify a place alongside a hospital-provided reference service.

A decision that can change with the task

Doximity Ask merits attention where its surrounding suite and the new reference access simplify existing work. OpenEvidence merits attention where its available evidence experience and institutional configuration match the clinician's needs. iatroX merits attention where applicable guidance and continued learning are priorities.

These are task-based recommendations, not test results. The sensible next step is a small, documented comparison using the clinician's ordinary questions, with source inspection included in the time measurement. The best first tab is the one that helps complete the actual task responsibly, not the one that wins the loudest announcement.

Frequently asked questions

Is DoxGPT a separate competitor to Doximity Ask?

Doximity now uses Ask for the product previously called DoxGPT. Older articles and searches may retain the former name, so product versions and dates should be checked before comparing claims.

Does UpToDate access prove Ask is more accurate than OpenEvidence?

No. An additional source relationship may improve the available evidence, but comparative accuracy requires a defined evaluation of the deployed products on relevant tasks.

When should a clinician consider iatroX alongside either platform?

When the remaining need concerns regional guidance, examination practice or working through a misconception. That is a complementary use case rather than a claim that every clinician should replace an established tool.

Explore iatroX's question banks when a clinical lookup exposes a topic worth practising.

More from the Journal